The $10-50 price range often includes mid-sized businesses with proven track records and plenty of growth runway ahead.
They also usually carry less risk than penny stocks, though they’re not immune to volatility as many lack the scale advantages of their larger peers.
Specialty pharmaceutical company Supernus Pharmaceuticals (NASDAQ:SUPN) reported revenue ahead of Wall Street’s expectations in Q1 CY2025, with sales up 4.3% year on year to $149.8 million. On the other hand, the company’s full-year revenue guidance of $615 million at the midpoint came in 1.6% below analysts’ estimates. Its GAAP loss of $0.21 per share was significantly below analysts’ consensus estimates.
Specialty pharmaceutical company Supernus Pharmaceuticals (NASDAQ:SUPN)
will be reporting earnings tomorrow after market close. Here’s what to look for.
Wall Street is overwhelmingly bullish on the stocks in this article, with price targets suggesting significant upside potential.
However, it’s worth remembering that analysts rarely issue sell ratings, partly because their firms often seek other business from the same companies they cover.
Personal health and wellness is one of the many secular tailwinds for healthcare companies. Despite the rosy long-term prospects, short-term headwinds such as COVID inventory destocking have harmed the industry’s returns -
over the past six months, healthcare stocks have collectively shed 12.7%. This performance was worse than the S&P 500’s 7.5% fall.
Uncover the potential of SUPERNUS PHARMACEUTICALS INC, an undervalued stock. NASDAQ:SUPN maintains a strong financial position and offers an appealing valuation.
Earnings results often indicate what direction a company will take in the months ahead. With Q4 behind us, let’s have a look at Eli Lilly (NYSE:LLY) and its peers.
Quarterly earnings results are a good time to check in on a company’s progress, especially compared to its peers in the same sector. Today we are looking at Organon (NYSE:OGN) and the best and worst performers in the branded pharmaceuticals industry.
Supernus Pharmaceuticals has been treading water for the past six months, recording a small loss of 1.6% while holding steady at $31.52. However, the stock is beating the S&P 500’s 7% decline during that period.
The end of an earnings season can be a great time to discover new stocks and assess how companies are handling the current business environment. Let’s take a look at how Collegium Pharmaceutical (NASDAQ:COLL) and the rest of the branded pharmaceuticals stocks fared in Q4.
As the Q4 earnings season wraps, let’s dig into this quarter’s best and worst performers in the branded pharmaceuticals industry, including Pfizer (NYSE:PFE) and its peers.
The end of an earnings season can be a great time to discover new stocks and assess how companies are handling the current business environment. Let’s take a look at how Royalty Pharma (NASDAQ:RPRX) and the rest of the branded pharmaceuticals stocks fared in Q4.
As the craze of earnings season draws to a close, here’s a look back at some of the most exciting (and some less so) results from Q4. Today, we are looking at branded pharmaceuticals stocks, starting with Supernus Pharmaceuticals (NASDAQ:SUPN).
Investors looking for hidden gems should keep an eye on small-cap stocks because they’re frequently overlooked by Wall Street.
Many opportunities exist in this part of the market, but it is also a high-risk, high-reward environment due to the lack of reliable analyst price targets.
As the Q4 earnings season comes to a close, it’s time to take stock of this quarter’s best and worst performers in the branded pharmaceuticals industry, including Corcept (NASDAQ:CORT) and its peers.
Quarterly earnings results are a good time to check in on a company’s progress, especially compared to its peers in the same sector. Today we are looking at Bristol-Myers Squibb (NYSE:BMY) and the best and worst performers in the branded pharmaceuticals industry.
Specialty pharmaceutical company Supernus Pharmaceuticals (NASDAQ:SUPN) reported Q4 CY2024 results beating Wall Street’s revenue expectations, with sales up 6% year on year to $174.2 million. On the other hand, the company’s full-year revenue guidance of $615 million at the midpoint came in 1.2% below analysts’ estimates. Its GAAP profit of $0.27 per share was significantly above analysts’ consensus estimates.
